Odyssey Therapeutics (ODTX) EV/EBIT: History & Chart

Odyssey Therapeutics, Inc.(ODTX)

Biotechnology · Boston, MA

$18.13-2.71 (-13.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Boston, MA

100 employees

odysseytx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gary D. Glick

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Odyssey Therapeutics, Inc. (ODTX)	$870.81M	N/A	N/A	N/A	N/A
SI-BONE, Inc. (SIBN)vs ›	$867.03M	N/A	N/A	N/A	N/A
QuidelOrtho Corporation (QDEL)vs ›	$857.16M	N/A	33.92x	15.14x	22.68x
Arbutus Biopharma Corp (ABUS)vs ›	$884.97M	5.91x	5.93x	5.93x	5.93x
Alumis Inc. (ALMS)vs ›	$855.38M	N/A	N/A	N/A	N/A
Bioventus Inc. (BVS)vs ›	$887.50M	18.14x	17.93x	24.19x	30.14x
Corvus Pharmaceuticals, Inc. (CRVS)vs ›	$887.99M	N/A	N/A	N/A	N/A
Rigel Pharmaceuticals, Inc. (RIGL)vs ›	$853.13M	9.56x	6.42x	12.92x	12.92x
SL Science Holding Ltd (SLBT)vs ›	$852.35M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$838.16M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Odyssey Therapeutics, Inc. (ODTX)

$870.81M

N/A

SI-BONE, Inc. (SIBN)vs ›

$867.03M

N/A

QuidelOrtho Corporation (QDEL)vs ›

$857.16M